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1. Introduction
Gestational Diabetes Mellitus (GDM) affects ~5% of all pregnancies and parallels the global
increase in obesity and type 2 diabetes. In the USA alone, GDM affects more than 135,000
pregnancies per year. Lifestyle changes that impact adversely on caloric balance are thought
to be a contributing factor in this emerging pandemic [1, 2]. The current ‘gold standard’ for
the diagnosis of GDM is the oral glucose tolerance test (OGTT) at 24–28 weeks of gestation [3,
4]. When GDM is diagnosed in the late second or early third trimester of pregnancy the
‘pathology’ is most likely well-established and the possibility to reverse or limit potential
adverse effects on perinatal outcomes may be limited [ 5]. Early detection of predisposition to
and/or onset of GDM, thus, is the first step in developing, evaluating and implementing
efficacious treatment. If such early detection tests were available, they would represent a major
advance and contribution to the discipline and afford the opportunity to evaluate alternate
treatment and clinical management strategies to improve health outcomes for both mother
and baby. Based upon recent technological developments and studies, we consider it realistic
that a clinically useful antenatal screening test can be developed. Unlike diseases such as cancer
where biomarkers need to be exquisitely specific, a useful antenatal screening test would
ideally be highly sensitive, but not necessarily highly specific. The consequence of a false
positive would be no worse than an erroneous triage to high-risk care.
Recent studies highlight the putative utility of tissue-specific nanovesicles (e.g. exosomes) in
the diagnosis of disease onset and treatment monitoring [6-11]. To date there is a paucity of
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data defining changes in the release, role and diagnostic utility of placenta-derived nanovesi‐
cles (e.g. exosomes) in pregnancies complicated by GDM.
The aim of this brief commentary, thus, is to review the biogenesis, isolation and role of
nanovesicles; and their release from the placenta. Placental exosomes may engage in paracel‐
lular interactions (i.e. local cell-to-cell communication between the cell constituents of the
placenta and contiguous maternal tissues) and/or distal interactions (i.e. involving the release
of placental exosomes into biological fluids and their transport to a remote site of action).
2. Exosome biogenesis and composition
2.1. Biogenesis
Exosomes are small [40-100 nm) membrane vesicles that are released following the exocytotic
fusion of multi-vesicular bodies with the cell membrane (Figure 1). They are characterised by:
a cup-shaped form: (a) a buoyant density of 1.13-1.19 g⁄ml [12, 13], (b) endosomal origin, and
(c) the enrichment of late endosomal membrane markers including Tsg101, CD63, CD9 and
CD81 [7, 14, 15]. While the process(es) of exosome formation remains to be fully elucidated,
available data support an endosomal origin and formation by the inward budding of multi-
vesicular bodies [16] (see Figure 2). Exosomes may also be directly transported from the Golgi
complex to multi-vesicular bodies [14].
Figure 1. Electron micrograph of circulating exosomes. Exosomes are 40-100 nm membrane vesicles with a density
ranging from 1.13-1.19 g/ml, characterised by a cup-shaped form and secreted by most cell types in vivo and in vitro.
Villous chorionic explant-derived exosomes were isolated by ultracentrifugation and purified using a sucrose gradient.
Scale bar = 100 nm.
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Figure 2. Schematic of exosome biogenesis and secretion. Exosomes are generated in the endosomal structure
participating the plasma membrane in this process, and secreted via constitutive endosomal pathways involving the
Golgi complex from various cell types. The exosomes contain specific proteins and miRNA as a new form of exosome-
mediated intercellular communication and with different biological function. In pathological pregnancies character‐
ised by compromised placental perfusion and ischaemia, such as GDM, exosome secreted from the placenta can
participate in an adaptive response of the mother and fetus and so interact with target tissue and modulate different
biological processes, such as immune response, cellular adhesion, development and metabolism.
Exosomes have been identified in plasma under both normal and pathological conditions. The
concentration of exosomal protein in plasma has been reported to increase in association with
disease severity and/or progression, and in response to oxidative stress. Cell membrane
budding and the deportation of cell membrane particles was originally considered as the
elimination of cell debris and associated with apoptosis and/or necrosis. Recent data, however,
suggest that the release of nanovesicles from cells may represent a normal mechanism for cell-
to-cell communication [17]. Packaging of exosomal contents appears to be a direct process in
which the ESCRT (endosomal sorting complex required for transport) systems play a signifi‐
cant role [18-20].
Exosomes are released from the placenta and the concentration of exosomes in maternal
plasma increases during normal pregnancy [21-23]. In vitro, exosomes are released from both
trophoblast cells and syncytium [24]. They contain placenta-specific proteins and miRNA and,
as such, may be differentiated from maternally-derived exosomes [25]. The concentration of
exosomes has been reported to increase in association with pre-eclampsia [22, 23, 26]. The role
of exosomes in the development and progression of GDM has yet to be established.
2.2. Composition
The exosomal content is highly dependent on the origin cell and on pre-conditioning of the
cell. One of the first exosomal proteomes characterised was from mesothelioma cells, in which
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38 different proteins were identified [27]. Studies in cancer cells show the great variability of
proteins expressed in exosomes [28-32]. In exosomes isolated from a human first trimester cell
line (Sw7 1) Atay et al., using an ion trap mass spectrometry approach, identified proteins
implicated in a wide range of cellular processes including: cytoskeleton structure (adhesion,
membrane transport, and fusion), ion channels, lysosomal degradation, molecular chaperones,
amino-acid metabolism, carbohydrate metabolism, lipid metabolism, oxydo-reductase
activity, protein synthesis and post-translational modifications, ubiquitin modifiers, signal
transduction, transcription factors and regulators, DNA replication, chromatin structural and
regulatory proteins, mRNA splicing, transcription/translation, post-translational protein
modification enzymes, nuclear structural proteins, integrins, complement and coagulation,
immune function, iron transport, and ER specific proteins. This study provides the first
extensive analysis of the proteome of the exosome-derived trophoblast cells [7]. The data
obtained in this study, highlights the extent of putative functional interactions that may be
mediated by exosomes.
While the composition of exosomes appears to be cell-specific, a subset of common proteins
has been identified. The lipid bilayer is composed of sphingomyelin [33, 34]. Among the most
commonly used markers for characterisation of exosomes are tetraspanin proteins, including:
CD63, CD81, CD9, and CD82. Other families of common proteins in all exosomes include
chaperone proteins such as: Hsc70 and Hsp90; cytoskeletal proteins including actin, tubulin
and myosin; transport proteins; and annexins [35]. Exosomes derived from antigen-presenting
cells (APC) express MHC-I and MHC-II on their surface [36-38]. During exosome biogenesis,
the phospholipid/protein ratio of exosomes may be regulated by the Golgi membranes [39].
Significantly, single cell types display the capacity to generate different subpopulations of
exosomes. Laulagnier et al. 2005 demonstrated that RBL-2H3 cells (basophilic leukemia cell
line) released two main subpopulations of exosomes that can be discriminated by protein and
lipid contents. The first subpopulation contains phospholipids obtained mainly from granules
and the second contains phospholipids from Golgi. In addition, proteins CD63, MHC-II, CD81-
containing exosomes accounted for 47%, 32%, and 21%, respectively, of total exosomes [39, 40].
3. Isolation of exosomes
Exosome research is a burgeoning discipline with over 2000 articles published in the last 3
years. The putative role of exosomes spans from intracellular signaling to biomarkers of disease
[41]. Germane to any study seeking to elucidate the physiological or pathophysiological role
of exosomes is their specific isolation. Several methods for isolating exosomes have been
developed and partially characterised. These isolation methods are primarily based on particle
size and density. By definition, exosomes are nanovesicles with a diameter of 30-100 nm.
Typically they display a density of 1.12 to 1.19 g/ml and express characteristic cell-surface
markers.
The most common method of separation involves a series of differential centrifugation to
remove intact cells and debris, and nuclei followed by size selective filtration (0.2 μm pore
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size) and sedimentation by ultracentrifugation (e.g. at 110,000 g for 1-2 hours [42, 43]. Exosomes
may be further purified by differential sedimentation on sucrose gradients or sucrose-
deuterium oxide (D2O) [ 7]. Alternative methods utilise size exclusion chromatography and
density gradient centrifugation [44] or solid-phase immunoaffinity capture (i.e. anti-MHC-II
Dynabeads) [38, 43, 45]. In the absence of specific, cell surface exosome markers, the veracity
of immuno-affinity methods remains to be established.
More recently a commercial kit for the isolation of the exosomes has been released (Exo‐
QuickTM, System Biosciences). The isolation process involves a simple one-step precipitation
[43, 46]. While the commercial kit provides significant advantage with respect to processing
time, the resulting preparation may not be equivalent to that obtained by ultracentrifugation
and differential segmentation. In our own laboratory, parallel preparations of exosomes using
both methods reveal differences in the biophysical characteristics of the exosomes isolated.
Exosome preparations isolated using the commercial kit were characterised by a great range
in particle diameter (30-300 nm, as estimated by transmission electron microscopy (TEM) and
have a higher protein content than similar preparations isolated using the ultracentrifugation
method. In addition, analysis of protein patterns in SDS-PAGE electrophoresis and western
blot against CD63, CD81 and CD9 show similar characteristics between exosomes from
ultracentrifuge and ExoQuickTM methods, however, we had to dilute ExoQuickTM samples ~
10 times to obtain comparable concentrations with ultracentrifuge methods in exosomes
isolated from trophoblastic cells (see Figure 3). Differences in exosome protein and mRNA
content and functional activity between different preparations remain to be established.
Figure 3. Typical characteristics of exosomes isolated from trophoblast cells. (A) Exosome protein pattern analy‐
sis. 10 ug of exosome proteins and trophoblast cell lysate were separated on 4-12% SDS-PAGE and stained with Sim‐
plyBlue™ SafeStain (Invitrogen). (B) Western blot characterisation of exosomes with antibodies against CD63, CD81
and CD9 for 4 different samples isolated with ultracentrifuge or ExoQuick™ methods.
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4. The role for exosomes in cell-to-cell communication
Recently, evidence supporting a role for exosomes in cell-to-cell communication has been
obtained [47, 48]. Exosome release may represent a significant, hitherto unappreciated,
communication mechanism between cells, host cell and microbes [47].
For example, exosome function as a carrier of specific molecules such as mRNA and miRNA
can interact with neighbouring cells or travel long distances in the bloodstream to reprogram
the phenotype and regulate their function [40]. In the placenta, exosome- derived trophoblastic
cells are able to reprogram monocytes to secrete specific cytokine profiles independent of cell-
to-cell contact [8]. Placental-derived exosomes may also play a role in modulating immuno‐
logical responses through the induction of lymphocyte apoptosis, [21, 44, 49].
4.1. Information encoding by exosomes
Exosomes have been reported to express a diverse range of cell surface receptors, proteins
(including, heat shock proteins, cytoskeletal proteins, adhesion molecules, membrane trans‐
port and fusion proteins), mRNA and miRNA with the potential to affect the acute and long-
term function of the cells with which they interact [50]. In addition, in the absence of energy
production, normal membrane phospholipid asymmetry is lost and amniophospholipids
translocate to the outer leaflet of the cell membrane and generate a fusogenic and pro-coagulant
surface. Given that exosomes circulate in blood, these fusogenic moieties may be masked by,
for example, annexin V.
In vitro effects of exposing cells to exosomal proteins has been reported and include: induction
of differentiation of stem cells [51], suppression of activation of natural killer cells and
macrophages [52, 53], and stimulation of cell migration [8, 54]. Putative roles of exosomes,
thus, include cell differentiation, immunomodulation and migration [55]. Exosomes are not
merely inert fragments of cell membrane but display capacity to affect cell function at remote
loci and possibly be a source of disease biomarkers.
Exosomes also contain miRNA that may transfer to other cells and alter the expression of the
transcriptome and ultimately cell phenotype. miRNAs are a class of small non-coding RNAs
that function as translational repressors involved in a variety of physiological and pathological
processes in animals [56, 57]. They act via binding to messenger RNA and, thus, prevent the
translation of the encoded protein. Previous studies have reported that miRNAs are involved
in the pathogenesis of diabetes and are required for pancreatic development and the regulation
of glucose-stimulated insulin secretion [50, 58]. Moreover, differences in the expression of
miRNA such as miR-146a, miR-21, miR-29a, miR-34a, miR-222, and miR-375 have been
reported in pancreatic β-cells, liver, adipose tissue, and/or skeletal muscle of animal models
of type 1 or type 2 diabetes [59]. Another study found that miR-20b, miR-21, miR-24, miR-15a,
miR-126, miR-191, miR-197, miR-223, miR-320, and miR-486 were lower in prevalent type 2
diabetes [60].
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4.2. Placental exosome release and effects
4.2.1. Placental exosome release
Exosomes are released by the placenta during pregnancy and their release may correlate with
pregnancy outcome. The syncytiotrophoblasts and cytotrophoblasts are the most abundant
cell types of the human placenta and sense and regulate oxygen and nutritional exchange
between mother and fetus during the pregnancy [61, 62]. Pathologies of pregnancy including
preeclampsia, intrauterine growth restriction (IUGR) and GDM are associated with placental
dysfunction [4, 63, 64] and may display differential and specific exosome release profiles.
It has been established that the concentration of exosomes in maternal peripheral blood is
greater than that observed in non-pregnant women [21]. In this study, exosomes of placental
origin were specifically isolated from the maternal blood using anti-PLAP (anti-placental-type
alkaline phosphatase) conjugated to agarose micro-beads. In peripheral blood mononuclear
cells (PBMC), placental exosomes suppressed T signalling components such as CD3-zeta and
JAK3, while inducing SOCS-2 [2 1]. These results are consistent with those of Taylor et al. [44,
65] who demonstrated the presence and composition of placenta-derived exosomes in
maternal circulation along with their effects on T cell activation markers. Exosomes appear to
play an essential role in preventing an excessive immune response and in the development of
autoimmunity in human pregnancy.
Recently, it has been demonstrated that placental miRNAs circulate in the blood of pregnant
women [66, 67]. For example, maternal plasma concentration of placental miRNA-141
increases with gestational age [66]. Placenta-specific miRNA-517A is released from chorionic
villous trophoblasts into maternal circulation, where it may affect maternal tissues (e.g.
maternal endothelium) during pregnancy [25]. There is a paucity of data, however character‐
ising the release of exosome from endothelial cells during normal and pathological pregnan‐
cies. It will be important to determine if the placenta communicates with the maternal
endothelium via microvesicles, and, if so, to elucidate the role and mechanism of action of
exosome pathologies associated with endothelial dysfunction, such as GDM. Placenta-derived
miRNAs, therefore, may be of utility as biomarkers of placental function and/or pregnancy
outcome. It remains to be elucidated how much of this “free” miRNA and mRNA is actually
contained within exosomes and thereby confers stability. Indeed, the exact mechanisms
involved in the release of miRNA from the placenta remain to be established. A recent study,
however, reported that miRNAs are selectively packaged into microvesicles and are actively
secreted [68-70]. miRNAs are also released from the syncytiotrophoblast to the maternal
circulation in the pregnancy packaged inside exosomes [25, 71].
4.2.2. Effects
There remains a paucity of data about the effect of placenta-derived exosomes on both fetus
and mother. The available data, however, support a role for placental exosomes in mediating
communication at the materno-fetal interface and, possibly, at the distal site within the mother.
Recent data show that trophoblast-derived exosomes induce proinflammatory cytokines such
IL-1 β in human macrophages cells [8]. Furthermore, in vitro exposure of PBMC and dendritic
The Role of Placental Exosomes in Gestational Diabetes Mellitus
http://dx.doi.org/10.5772/55298
35
cells to exosomal proteins induce differentiation of stem cells; suppression of activation of
natural killer cells and macrophages; and stimulation of cell migration [53, 72, 73]. Interest‐
ingly, protein analysis revealed that exosome release from trophoblast cells increases with low
oxygen tension and their exosome promote the cell migration in extravillous cytotrophoblast
(HTR- 8) (Salomon et al. manuscript in preparation).
5. Exosomes and GDM
Exosomes released from the placentae of women with GDM may alter maternal physiology.
Via a process of exosomal placento-maternal transfection a “payload” of receptors, proteins
and/or oligonucleotides” that have been specifically pre-conditioned by the GDM placenta
may be delivered to maternal response systems. Such mediators include: vascular, pancreatic
and adipose tissues, and the innate immune response system. The extent and impact of
placenta-derived exosomes on maternal physiology, however, remains to be elucidated.
In addition to a placento-maternal transfection pathway, trophoblasts or placental mesenchymal
stem cells (MSCs) may induce paracellular effects in association with GDM. For example, in
placental villi, exosomes released by perivascular MSCs may alter transport activity within
the placental vascular endothelium (e.g. the glucose transport GLUT 3) and thus the delivery
of energy substrates to the fetus.
In support of the role of exosomes in modulating glucose homeostasis, Deng et al., reported
that exosomes isolated from adipose tissue induce differentiation of monocytes into activated
macrophages and promote insulin resistance in an obese mouse model [74]. Exosomes isolated
from mouse insulinoma induce the secretion of inflammatory cytokines including IL-6 and
TNF-α in splenocytes cultured from non-obese diabetic mice (NOD) [75]. In this regards, these
cytokines as well as other inflammatory mediators play an important role in glucose tolerance
and insulin sensitivity dysregulation in women with previous GDM.
5.1. The effects of hyperglycaemia and oxidative stress on exosome release
GDM is a state of hyperglycaemia and increased oxidative stress [76]. In addition, hypergly‐
caemia-induced oxidative stress makes an important contribution to the aetiology of GDM
[77], with consequences for both mother and baby [78]. In support of an aetiological role of
hypoglycaemia and attendant oxidative stress in poor pregnancy outcome, the HAPO study
reported a strong and continuous association between maternal glucose concentrations and
pregnancy outcome and confirmed a relationship between birth weight and maternal hyper‐
glycaemia [79, 80].
Reactive oxygen species (ROS) include oxygen ions such as superoxide ions and hydrogen
peroxide (H2O 2) that are generated continuously during cellular metabolism. GDM pregnan‐
cies are characterised by an overproduction of ROS and free radicals and impaired antioxidant
capacity [81]. Oxidative stress and increased exosome release are common features of many
pathologies including: cancer, kidney disease, hypertension, and preeclampsia. It remains to
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be established whether or not exosome release in these circumstances is a paraphenomenon
of, or an adaptive response to, increased ROS formation and oxidative stress.
GDM is a syndrome that leads to feto-placental vascular endothelial dysfunction involving
higher nitric oxide (NO) concentrations and increases of oxidative state and vascular resistance
[63, 82]. Exosomes – endothelial cell interactions may result in activation of NO synthesis via a
number of mechanisms. Exosomes isolated from platelets obtained from patients with septic
induced endothelial dysfunction through the NADPH oxidase-dependent release of superox‐
ide and have been implicated in the induction of NO and peroxinitrite. NO synthase is also
induced by miR-203. miRNA-203 has been identified in exosomes [83]. It remains to be establish‐
ed whether or not miRNA-203 is present in exosomes isolated from women with GDM.
In non-gestational tissues, the available evidence supports an active role for exosomes in
regulating cellular redox status. For example, oxidative stress enhances exosome release from
Jurkat and Raji cell lines and the resultant increase in NKG2D receptor bioactivity impairs
cytotoxic response [84]. In 3T3-L1 adipocytes, oxidative stress increases microvesicle release
[85]. Melanoma-derived exosomes induce ROS production in T cells compared to exosomes
from normal cells, suppressing the immune response and improving carcinogenic invasion
[86]. Exosomes isolated from mouse mast cells MC/9 exposed to oxidative stress alter the
response of others cells to oxidative stress [87], increasing their resistance to oxidative stress
and reducing cell death. Interestingly, the mRNA content of exosomes produced under
oxidative stress conditions differ from those produced under normal conditions. These data
are consistent with the observations of Atay et al. [7, 8], Luo et al., [25] and Taylor et al. [83] who
similarly report cell- and condition-specific variation in exosomal protein, mRNA and miRNA
content.
5.2. Exosome biomarkers of GDM
In addition to their putative functional involvement in the pathophysiology of pregnancy,
placental-derived exosomes may be of utility as diagnostic markers of GDM in asymptomatic
women.
In 2011, the American Diabetes Association (ADA) and the International Association of
Diabetes and Pregnancy Study Groups (IADPSG) revised recommendations regarding GDM.
It is now recommended that patients at increased risk for type 2 diabetes be screened for
diabetes using standard diagnostic criteria at their first prenatal visit (ADA 201 2). Currently,
GDM is diagnosed in the late second or early third trimester of pregnancy. Pathology is
probably already established by this time and reversal of the potential adverse perinatal
outcomes may be limited. The lack of a reliable early test for GDM has hampered the devel‐
opment of useful intervention therapies that may impact not only on the acute but also the
long-term health outcomes [88-90]. Thus, there is a need to diagnose and predict GDM earlier
so that appropriate management can be initiated and tailored to the needs of the patient in
order to minimise perinatal complications and their sequelae.
Currently, the diagnosis of GDM is between 24-28 weeks of gestation by an oral glucose
tolerance test. The aim of the treatment for GDM is to maintain the glucose level in euglycaemia
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with dietary modifications or in some cases with insulin therapy, however, when it is diag‐
nosed, the pathology is established and the clinical and obstetric management is limited [5, 91].
The quantitation of exosomes and/or exosome-specific content may be of diagnostic utility [14,
43, 83, 92, 93]. Exosomes are found in all body fluids tested to date including blood, urine,
saliva and breast milk. They can be obtained by minimally invasive methods (blood) or non-
invasive methods (using urine or saliva) [94]. Several studies have demonstrated the putative
utility of exosomes as biomarkers, particularly in cancers, where exosomal protein is correlated
with disease burden.
The measurement of exosomal miRNA in biofluids has proven of utility in cases of lung cancer,
colorectal cancer, prostate cancer and diabetes [95-99].
Zhao et al. isolated miRNA from blood circulation at 16-19 gestational weeks. Interestingly,
these authors found that the expression of miRNA-132, miRNA-29a and miRNA-22 were
decreased in GDM women compared with normal pregnancies in similar gestational weeks
[70]. Finally, there are few reports suggesting that mesenchymal stem cell and trophoblast
cells-derived exosomes may serve as therapeutic agents for use in regenerative medicine to
repair damaged tissue [100, 101].
Finally, in normal pregnancies, the placenta secretes significant amounts of macro- and microve‐
sicles, including exosomes [22, 26]. We suggest that in pregnancies complicated by GDM,
oxidative stress and hyperglycaemia increase the release of exosomes from the placenta into the
maternal circulation during in the first trimester of pregnancy. The quantification and character‐
ised of exosomes in the blood of these pre-symptomatic women, thus, may be of utility as an early
biomarker of disease onset. Furthermore, we propose that during first trimester, pre-symptomat‐
ic women who subsequently develop GDM: have higher plasma concentrations of placental-
derived exosomes; and a different exosomal protein and miRNA profile than women who
experience a normoglycaemic pregnancy. These characteristics could potentially be used for
diagnostic markers for exosome profiling to screen asymptomatic populations.
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